FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
4 hours ago
- #FDA
- #mRNA Vaccine
- #Influenza
- FDA advisory committee unanimously voted (9-0) to support Moderna's seasonal mRNA flu vaccine.
- Moderna's mRNA-1010 (mFlusiva) showed 27% higher efficacy against flu in adults over 50 compared to standard flu shot.
- Stronger immune responses were observed in older adults (65+) compared to high-dose flu vaccine.
- Safety profile of the vaccine is generally good, with studies described as well-conducted and robust.
- mRNA platform allows rapid development and preparedness for emerging or pandemic strains.